Committee on the Review

The Parties agree to adhere to the principles of medical confidentiality in relation to Clinical Trial Subjects involved in the Clinical Trial. Personal data shall not be disclosed to the Sponsor by the NHS Trust save where this is required directly or indirectly to satisfy the requirements of the Protocol or for the purpose of monitoring or adverse event reporting. The Sponsor shall not disclose the identity of Clinical Trial Subjects to third parties without prior written consent of the Clinical Trial Subject, in accordance with the requirements of the Data Protection Act 1998 and the principles set out in the Report of the Caldicott Committee on the review of patient identifiable information dated December 1997, a copy of which the NHS Trust shall supply to the Sponsor on request. 

Committee on the Review of Medicines. Systematic review of the benzodiazepines. BrMedJ 1980 280 910-912. 

It is for those already dependent on tranquillisers, for a few weeks or over twenty-five years, that attention is now being directed towards finding a safe effective way to help those who wish to withdraw. Increasingly it is being recognised that tranquillisers were only ever of use as a temporary measure of symptomatic relief (Committee on the Review of Medicines 1980). Those who withdraw from them may also require further help to deal with psychosocial problems, of which anxiety was an indication. 

How soon the withdrawal syndrome starts is partly dependent upon the half-life of the tranquilliser being taken, and whether other benzodiazepines are also being used (for example, hypnotics). If the half-life is shorter (that is, less than twelve hours), then a person may experience withdrawal between doses. However, if the tranquilliser is longer acting, then withdrawal can start within three to ten days of any reduction (Committee on the Review of Medicines... 

In 1987, the NRC Committee on the Review and Evaluation of the Army Chemical Stockpile Disposal Program (Stockpile Committee) was formed to advise the CSDP. Construction and systemization (operational testing) of the first fully integrated baseline incineration system, the Johnston Atoll Chemical Agent Disposal System (JACADS), was completed in June 1990... 

Dr. Veenema has served as a reviewer to the Institute of Medicine Committee on the Review Panel for the Smallpox Vaccination Implementation, Jane s Chem-Bio Handbook, 2nd Edition, and serves on the editorial board for the journal Disaster Management and Response, sponsored by the Emergency Nurses Association. Dr. Veenema is an Associate Editor for the Journal of Disaster Medicine and Public Health Preparedness, sponsored by the American Medical Association. 

Homoeopathic Products. Earlier advisory committees, the Committee on the Review of Medicines, the Committee on Dental and Surgical Materials, the Committee on Radiation from Radioactive Medicinal Products, and the Safety and Efficacy sub-committee, have been dis-established as circumstances have changed. 

The number of PLRs that lapsed or were revoked or suspended in the UK between 1971 and 1982 was 22 376, but the number of PLRs that were converted into full Product Licences was only 598. In 1991 the Committee on the Review of Medicines was deemed to have completed the review of PLRs in the UK and it was disbanded on 31 March 1992. 

Charles E. Kolb, Chair, graduated from the Massachusetts Institute of Technology with a B.S. in chemical physics and from Princeton University with an M. A. and a Ph.D. in physical chemistry. Dr. Kolb is president and chief executive officer of Aerodyne Research, Inc., in Billerica, Massachusetts. His principal research interests include atmospheric and environmental chemistry, combustion chemistry, materials chemistry, and the chemical physics of rocket and aircraft exhaust plumes. He has served on several National Aeronautics and Space Administration panels dealing with environmental issues as well as on six previous National Research Council (NRC) committees and boards dealing with atmospheric and environmental chemistry. Dr. Kolb also served on the NRC s Committee on the Review and Evaluation of the Army Chemical Stockpile Disposal Program (member, 1993-1998 vice chair, 1998-2000). He is a fellow of the American Physical Society, the American Geophysical Union, the American Association for the Advancement of Science, and the Optical Society of America. 

Committee on the Review of Railway Finances (1983) Railway Finances Report of a Committee Chaired by Sir David Serpell, London HMSO. 

MAFF (1979), Interim Report on the Review of the Colouring Matter in Food Regulations, FAC/REP / 29, Ministry of Agriculture, Eisheries and Eood, Eood Additives and Contaminants Committee, HMSO, London, 1973. 

USA Patriot Act A Review for the Purpose of Reauthorization, Hearing before the Committee on the Judiciary House of Representatives, Serial No. 109-12, US Government Printing Office, Washington, 2005. 

At the same time. Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) evaluated FETAX methodology based on the inter-laboratory studies and published a review document in 2000 (5). The expert panel concluded that FETAX was not sufficiently validated for regulatory use due to the intra- and inter-laboratory variability (6). Nonetheless, the assay was developed in our laboratory for use as a predictive screening assay. 

Method-dependent measurements can be grouped by sector. For example, in the clinical fields there are cases where some higher order reference materials are required for IVD methods, such as for determination of glucose in human serum. It is also required of reference laboratories in specific measurement methods. These issues are now under the responsibility of JCTLM (Joint Committee on the Traceability of Laboratory Medicine of CCQM). CENAM has developed a reference material for glucose and cholesterol determination in human serum, and certified by IDMS, which is under review by JCTLM for the use by reference laboratories in any country applying a reference method. 

Three more National Research Council committees (the first, second, and third Committees on the Biological Effects of Ionizing Radiations—BEIR I, II, and III) issued reports in 1972, 1977, and 1980.301-303 They emphasized risk estimation, rather than recommendation of standards. There also has been discussion of carcinogenicity as a low-dose, delayed effect. The United Nations, through its Scientific Committee on the Effects of Atomic Radiation, has continued to produce periodic encyclopedic reviews of the literature.1+68-473... 

In this report, the Subcommittee on Chronic Reference Doses for Selected Chemical-Warfare Agents of the National Research Council s (NRC s) Committee on Toxicology reviews the scientific validity of the Army s interim values for the six chemical-warfare agents—GA, GB, GD, VX, sulfur mustard, and lewisite. The NRC report is intended to be useful to the Army in making site-specific cleanup decisions. 

After comments are reviewed and changes are made, the revised draft is reviewed by the Committee on the Japanese Pharmacopeia and then by the Executive Committee of the Central Pharmaceutical Affairs Council before it is submitted for publication in the JP. 

MAFF. Food Advisory Committee report on the review of the use of additives in foods specially prepared for infants and young children. FdAC/REP/12. London HMSO, 1992. 

FDA reviewed the scientific evidence and recommendations of various scientific bodies, including the Institute of Medicine, National Academies of Science, an expert panel for the National Cholesterol Education Program, and the Advisory Committee on the Dietary Guidelines for Americans 2000. On July 9, 2003, the FDA issued a regulation requiring manufacturers to list trans fatty acids on the Nutrition Facts panel of the labels of foods and some dietary supplements. The new requirement will mean that manufacturers of most conventional foods and some dietary supplements will have to list in the Nutrition Facts panel the trans fat content of the product, in addition to the information about its overall fat content and saturated fat content. Dietary supplement manufacturers will need to list trans fat, as well as saturated fat and cholesterol, on the Supplement Facts panel when their products contain more than trace amounts (0.5 g) of trans fat. Examples of dietary supplements that may contain trans fat are energy and nutrition bars. 

Based on its review and analysis in Chapters 1 through 5 of incidents at two operating chemical demilitarization sites, JACADS and TOCDF, the Committee on the Evaluation of Chemical Events at Army Chemical Agent Disposal Facilities developed the following findings and recommendations. 

---